Onesource Specialty Pharma Intrinsic Value
ONESOURCE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹532.56 | ₹426.05 - ₹639.07 | -70.0% | EPS: ₹3.68, Sector P/E: 22x |
| Book Value Method | asset | ₹4438.00 | ₹3994.20 - ₹4881.80 | +150.0% | Book Value/Share: ₹5346.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2756.36 | ₹2480.72 - ₹3032.00 | +55.3% | Revenue/Share: ₹1378.18, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3461.73 | ₹3115.56 - ₹3807.90 | +95.0% | EBITDA: ₹440.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹532.56 | ₹479.30 - ₹585.82 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹532.56 | ₹479.30 - ₹585.82 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹665.34 | ₹598.81 - ₹731.87 | -62.5% | EPS: ₹3.68, BVPS: ₹5346.36 |
Want to compare with current market value? Check ONESOURCE share price latest .
Valuation Comparison Chart
ONESOURCE Intrinsic Value Analysis
What is the intrinsic value of ONESOURCE?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Onesource Specialty Pharma (ONESOURCE) is ₹665.34 (median value). With the current market price of ₹1775.20, this represents a -62.5% variance from our estimated fair value.
The valuation range spans from ₹532.56 to ₹4438.00, indicating ₹532.56 - ₹4438.00.
Is ONESOURCE undervalued or overvalued?
Based on our multi-method analysis, Onesource Specialty Pharma (ONESOURCE) appears to be trading above calculated value by approximately 62.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.95 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.28 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 0.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 28.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.20x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Onesource Specialty Pharma
Additional stock information and data for ONESOURCE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-68 Cr | ₹-169 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-107 Cr | ₹-107 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-163 Cr | ₹-197 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-416 Cr | ₹-762 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-118 Cr | ₹-222 Cr | Negative Cash Flow | 3/10 |